NCT01279291 2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
Clinical Trials
10 trialsNCT01170650 2021-09-30
PROCEED
Endocyte
Phase 3 Terminated
NCT00913835 2019-09-26
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00523380 2017-03-01
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Novo Nordisk A/S
Phase 2 Completed
NCT02081495 2016-11-11
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT01815294 2015-12-04
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01715168 2015-01-15
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Azaya Therapeutics, Inc.
Phase 1 Unknown
NCT00722592 2015-01-07
PRECEDENT
Endocyte
Phase 2 Completed